SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its meme-driven narrative of overcoming financial hardship and "slapping" the broken system. Active community engagement and a shared vision of success are key talking points. Some are pointing to potential catalysts and developments that could fuel a significant move.

The Internet Computer is a decentralized cloud blockchain that pursues the $1+ trillion cloud market - hosting apps, websites and enterprise systems, fully onchain, where they benefit from extraordinary security and resilience, can do multi-chain token processing, and can be administered in a decentralized way for safety.  A core purpose is “self-writing cloud,” where AI creates apps for mass market users, which are sophisticated and secure, in response to instructions they provide over chat.  The ICP token is burned powering onchain apps, and is a cryptocurrency used in network governance staking.  It’s easy to try - use AI to create onchain apps (e.g. caffeine.ai) or use an online IDE to write serverless code yourself (e.g. icp.ninja)!

Internet Computer

Internet Computer (ICP) is trending as the community discusses its recent price surge and potential for further gains, possibly fueled by speculation around a Coinbase listing. Community members are debating whether to hold or take profits, while others point to the project's technology and criminally low market cap as reasons for optimism. Technical analysis suggests analysts are watching $8.00 as the next resistance level, with the $7.40-$7.50 zone providing a key near-term floor.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to its recent Q3 earnings report, which revealed no revenue and a net loss, sparking debate about the company's valuation and future prospects. Community discussions revolve around the lack of current revenue versus its high market cap, potential for future growth in the nuclear energy sector, and the impact of government support. Bearish sentiment is growing, with many anticipating a price correction.

Leifras Co., Ltd. Engages in sport training, event and alliance & club activity support and healthcare activities. It provides services related to the organization and operations of sports schools and sports events for children and it also operate a robust social business sector, dispatching sports coaches to meet various community needs. The company was founded by Kiyotaka Ito on August 28, 2001 and is headquartered in Tokyo, Japan.

Leifras Co Ltd - ADR

LEIFRAS Co., Ltd. American Depositary Shares

Leifras Co. Ltd. ($LFS) is trending after a significant rally, reportedly fueled by recent revenue growth in education and social business sectors. Community discussions mention potential short squeezes due to the stock's low float and comparisons to other high-momentum stocks like $LUCY and $GLTO. Traders are also speculating about sympathy plays in related Japanese stocks and the possibility of after-hours continuation.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending amid speculation around potential buyout offers, fueled by recent activity in the obesity drug market. The community is closely watching for any news or announcements related to ongoing discussions and potential partnerships. Some believe VKTX is undervalued, while others caution against over-optimism.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk ($NVO) is trending due to the announcement of a deal with the Trump administration to cut prices on GLP-1 weight loss drugs, causing mixed reactions in the community; while some see this as positive for expanding access, others worry about margin erosion and increased competition with Eli Lilly ($LLY). Community members are actively discussing potential catalysts like FDA approval of oral Wegovy, as well as speculation around M&A activity, particularly regarding Metsera ($MTSR) and Viking Therapeutics ($VKTX).

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Cel-Sci Corp.

Cel-Sci Corp

CVM is trending as investors await a potential decision from Saudi Arabia regarding Breakthrough Medicine Designation for Multikine, a cancer immunotherapy. Community discussions revolve around the likelihood of approval and the potential impact on the company's financial outlook and partnership with Dallah Pharma. Some caution against premature optimism, noting the rigorous regulatory process and mixed historical results.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global ($VG) is trending amid discussions about a new partnership with Mitsui and the potential impact on LNG flow to Japan. Community members are calculating the value of the deal in the trillions and debating the implications of settlements and arbitration cases, particularly regarding Shell. Despite some negative sentiment and a recent arbitration loss, many see long-term potential due to increased LNG demand and VG's growing role as an exporter.

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Quoin Pharmaceuticals Ltd - ADR

QNRX is trending due to news of a significant private placement expected to fund its rare disease therapies, sparking high volatility and a surge in trading volume. Community discussions revolve around potential short squeezes, the stock's low float, and upcoming milestones, with some traders expressing optimism for further gains while others remain cautious due to dilution concerns and market conditions. The stock's significant price movement and potential for future rallies are also key talking points.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending as investors closely monitor the upcoming CHMP meeting, where Anavex will present on its Alzheimer's drug, Blarcamesine, with the community actively discussing approval odds and potential market impact. While the need for an oral explanation has sparked some uncertainty, many bulls remain optimistic, citing the drug's safety profile, potential efficacy, and convenience compared to existing treatments. Community members are debating the potential for conditional approval and speculating on the long-term implications for Anavex and the broader Alzheimer's treatment landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
